Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ORIC Pharmaceuticals
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
Today 16:59 EDT
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
May 29, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
April 15, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
April 04, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
March 11, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
March 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
February 14, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
January 31, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
January 22, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
January 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
December 11, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
November 06, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
October 21, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
October 17, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Tickers
ORIC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.